The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through its LillyDirect platform.

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple ...

US pharma major Eli Lilly (NYSE: LLY) has lowered the price of Zepbound (tirzepatide) single-dose vials on its Lilly Direct platform, widening access in a fast-moving obesity market. The 2.5-mg ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

President Donald Trump announced a new agreement with Eli Lilly and Novo Nordisk to expand coverage and lower prices for popular obesity drugs Zepbound and Wegovy, part of the GLP-1 class of ...

Eli Lilly has lowered the price of its GLP-1 drug Zepbound (tirzepatide) in single-dose vials, with the starting dose now available for $299 per month through the company’s direct-to-consumer platform ...